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Abstract
Telomeres are considered anti-cancer targets, as telomere mainte-
nance above a minimum length is necessary for cancer growth.
Telomerase abrogation in cancer-prone mouse models, however,
only decreased tumor growth after several mouse generations
when telomeres reach a critically short length, and this effect was
lost upon p53 mutation. Here, we address whether induction of
telomere uncapping by inhibition of the TRF1 shelterin protein can
effectively block cancer growth independently of telomere length.
We show that genetic Trf1 ablation impairs the growth of p53-null
K-RasG12V-induced lung carcinomas and increases mouse survival
independently of telomere length. This is accompanied by induc-
tion of telomeric DNA damage, apoptosis, decreased proliferation,
and G2 arrest. Long-term whole-body Trf1 deletion in adult mice
did not impact on mouse survival and viability, although some
mice showed a moderately decreased cellularity in bone marrow
and blood. Importantly, inhibition of TRF1 binding to telomeres by
small molecules blocks the growth of already established lung
carcinomas without affecting mouse survival or tissue function.
Thus, induction of acute telomere uncapping emerges as a poten-
tial new therapeutic target for lung cancer.
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Introduction
Lung cancer is the leading cause of cancer-related deaths worldwide
(Siegel et al, 2012). Adenocarcinoma, a subtype of non-small-cell
lung cancer (NSCLC), is the single most common form of lung
cancer, comprising 29% of cases (Herbst et al, 2008). The overall
5-year survival rate is of only 15%, due to the long-term ineffective-
ness of current therapies and late stage at time of diagnosis (Siegel
et al, 2012).
Activating mutations in the K-Ras proto-oncogene are found in
30% of human NSCLC (Rodenhuis et al, 1988). Mutations in the
p53 tumor suppressor gene are also common in NSCLC, affecting
50% of the cases (Chiba et al, 1990). Several lung cancer mouse
models have been generated that recapitulate human NSCLC by
using K-Ras-mutated alleles (Johnson et al, 2001; Guerra et al,
2003). In particular, the lox-stop-lox-K-RasG12V knock-in mouse
model, in which endogenous expression of the K-RasG12V oncogene
is induced upon Cre recombinase expression, has allowed the study
of early stages of lung tumorigenesis (Guerra et al, 2003). Combina-
tion of K-RasG12D expression with p53 deficiency recapitulates late-
stage lung cancers, including occurrence of invasion, stromal
desmoplasia, and metastasis (Jackson et al, 2005). The lox-stop-lox-
K-RasG12V mouse model has been instrumental to test novel thera-
peutic strategies against lung cancer, such as c-Raf, Cdk4, EGF
receptor, and Notch (Puyol et al, 2010; Blasco et al, 2011; Maraver
et al, 2012). However, to date all therapeutic targets tested have
failed to impair the growth of K-RasG12D-induced lung tumors in the
context of p53 deficiency (Navas et al, 2012).
Telomeres are specialized heterochromatin structures at the
ends of chromosomes composed of tandem TTA (Perera et al,
2008) GGG repeats bound by a protein complex, known as
shelterin, that protects chromosome ends from degradation and
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DNA repair activities (Blasco, 2007; Palm & de Lange, 2008).
The shelterin complex is composed of six core proteins,
including the telomeric repeat binding factor 1 or TRF1 (de
Lange, 2005).
During each cell division cycle, telomeres shorten owing to the
incomplete replication of chromosome ends by conventional DNA
polymerases, the so-called end-replication problem (Watson, 1972;
Olovnikov, 1973). Telomerase can elongate telomeres de novo, thus
compensating for telomere shortening in those cells where it is
expressed, such as pluripotent and adult stem cells, as well as the
majority of late-stage human cancers (Shay & Bacchetti, 1997; Deng
& Chang, 2007; Shay & Wright, 2010). Telomerase is composed of a
catalytic subunit or TERT and of an RNA component or Terc which
is used as template for the de novo synthesis of telomeric repeats
(Greider & Blackburn, 1985).
Telomeres are usually shorter in tumor cells compared to the
healthy surrounding tissue (de Lange et al, 1990; Shay & Wright,
2010). To maintain a minimum functional telomere length, 80–90%
of human tumors reactivate telomerase (Kim et al, 1994; Shay &
Bacchetti, 1997; Joseph et al, 2010), and the remaining activate an
alternative mechanism to maintain telomeres, known as ALT, based
on recombination between telomeric sequences (Bryan et al, 1997).
Supporting a role of telomerase deregulation in human cancer,
single nucleotide polymorphisms in the locus of human hTERT are
associated with various malignancies, including glioma, lung
cancer, urinary bladder cancer, melanoma, and breast cancer,
among others (McKay et al, 2008; Wang et al, 2008; Rafnar et al,
2009; Shete et al, 2009; Petersen et al, 2010; Melin et al, 2012;
Mocellin et al, 2012; Bojesen et al, 2013; Garcia-Closas et al, 2013;
Horn et al, 2013; Huang et al, 2013). These findings lead to the
development of telomerase-based therapeutic strategies for cancer
treatment, some of which are currently tested in clinical trials (Buse-
man et al, 2012).
Telomerase abrogation in the context of mouse models, however,
has only shown anti-tumorigenic activity after several mouse gener-
ations of telomerase-deficient Terc/ mice, when telomeres reach a
critically short length, and this anti-tumorigenic effect is abrogated
in the absence of p53 (Chin et al, 1999; Greenberg et al, 1999).
Similarly, in the context of the K-RasG12V lung carcinogenesis mouse
model, telomerase deficiency decreased tumor growth only after five
mouse generations, and this effect was lost upon p53 abrogation
(Perera et al, 2008).
To circumvent these potential shortcomings of telomerase inhibi-
tion, here we set out to address the therapeutic effect of acute
telomere uncapping owing to Trf1 abrogation (Martinez et al, 2009)
in the K-RasG12V lung cancer model (Guerra et al, 2003). TRF1 is an
essential component of shelterin and, in addition, it is enriched in
adult stem cells and pluripotent stem cells, suggesting that its inhibi-
tion may also target cancer stem cells (Boue et al, 2010; Schneider
et al, 2013). In this regard, we have previously shown that TRF1
deletion in stratified epithelia could promote cancer development
when in a p53-deficient background (Martinez et al, 2009).
However, in contrast to POT1, another shelterin component, TRF1,
has not been found mutated in human cancer (Ramsay et al, 2013;
Robles-Espinoza et al, 2014; Shi et al, 2014; Bainbridge et al, 2015).
Indeed, TRF1 has been reported to be overexpressed in several
tumor types (Matsutani et al, 2001; Ohyashiki et al, 2001; Fujimoto
et al, 2003; Oh et al, 2005; Bellon et al, 2006). Thus, here we set
out to address whether Trf1 deletion in the context of oncogenic
K-Ras-induced lung cancer mouse model would act as a tumor
suppressor or as an oncogene.
We found that Trf1 genetic ablation effectively reduces the size
and malignancy of p53-null K-RasG12V lung carcinomas and
increases mouse survival. This tumor-suppressive effect of Trf1
deficiency occurs already at the first mouse generation and is inde-
pendent of telomere length. Furthermore, long-term conditional
whole-body Trf1 deletion in adult mice does not affect mouse
viability and survival. Moreover, we show that chemical inhibition
of TRF1 can be achieved in vivo by using small molecules, which
effectively impair the growth of already established lung adenocarci-
nomas without affecting mouse and tissue viability. Thus, acute
telomere uncapping owing to TRF1 inhibition represents a novel
potent therapeutic strategy for K-Ras-induced lung cancer.
Results
Trf1 deficiency impairs immortalization of MEFs expressing the
K-RasG12V oncogene even in a p53-deficient background
To assess the effect of Trf1 abrogation in the context of lung cancer
induced by expression of the K-RasG12V oncogene, we crossed
K-Ras+/LSLG12Vgeo mice (designated from now on as K-Ras+/G12V)
(Guerra et al, 2003) to a strain carrying a floxable allele of Trf1
(Trf1lox/lox) either wild-type or deficient for p53 (p53/) (Martinez
et al, 2009) (Fig. 1A). First, we isolated primary (passage 2) mouse
embryonic fibroblasts (MEFs) and transduced them with a retrovi-
rus encoding the Cre recombinase (pBabe-Cre). This allowed the
expression of the resident K-RasG12V oncoprotein simultaneously
with the deletion of exon 1 of the Trf1lox allele (Fig 1A). A p53-null
background was used to allow for the growth of Trf1-deleted cells,
which otherwise show severe proliferative defects (Supplementary
Fig S1A) (Martinez et al, 2009; Thanasoula et al, 2010). While
Trf1+/+ K-Ras+/G12V p53/ MEFs showed a 16-fold increase in cell
number at day 7 post-plating, Trf1D/D K-Ras+/G12V p53/ MEFs
only increased their population by fourfold in the same time
(Supplementary Fig S1A), indicating a severe growth impairment of
Trf1-deficient K-RasG12V-expressing cells compared to the Trf1+/+
K-Ras+/G12V p53/ controls.
To address how Trf1 ablation impairs the growth of K-RasG12V-
expressing MEFs, we first analyzed cellular senescence by the
b-galactosidase senescence-associated activity. Trf1D/D K-Ras+/G12V
p53+/+ MEFs presented 1.9-fold higher percentage of senescent cells
7 days post-plating compared to Trf1+/+ K-Ras+/G12V p53+/+ MEFs
(Supplementary Fig S1B) (Martinez et al, 2009). Of note, p53
deficiency did not abolish Trf1 deficiency-mediated senescence.
Indeed, Trf1D/D K-Ras+/G12V p53/ MEFs showed a 21-fold higher
percentage of senescent cells compared to Trf1+/+ K-Ras+/G12V
p53/ MEFs 7 days post-plating (Supplementary Fig S1B), most
likely reflecting an additive effect of K-Ras oncogene-induced
senescence and Trf1 deficiency-induced senescence (Serrano et al,
1997; Martinez et al, 2009). No significant differences in apoptosis
were detected between genotypes by caspase-3 activation (Supple-
mentary Fig S1C). Thus, Trf1 abrogation in MEFs expressing mutant
K-Ras leads to higher numbers of senescent cells even in the absence
of p53.
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Next, we addressed the effect of Trf1 abrogation in immortaliza-
tion of MEFs. To this end, we performed a colony formation assay,
which reflects on the clonogenic capacity of individual cells.
p53-proficient MEFs did not form any colonies in agreement with
the fact that p53 wild-type MEFs do not spontaneously immortalize





Figure 1. Efficient oncogenic K-RasG12V expression and Trf1 depletion in lung lesions.
A Genetic model. Trf1lox and K-RasLSLGV12 alleles are depicted before and after Cre-mediated excision.
B In vivo imaging schedule. Eight- to ten-week-old mice were intratracheally infected with adeno-Cre, mice were analyzed every 2 weeks by computerized tomography
(CT), and 22 weeks post-infection, a positron emission tomography (PET) was performed. Mice were sacrificed 24 weeks post-infection for further histological
analysis.
C TRF1 immunofluorescence of the lungs. Notice the absence and presence of TRF1 signal in the carcinomas and surrounding healthy tissue of Trf1D/D mice,
respectively.
D Analysis of Trf1 excision by PCR. Notice the completed excision in carcinomas of Trf1lox/lox lungs.
E Detection of b-galactosidase activity in the lungs as a surrogate marker of oncogenic K-RasG12V expression.
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et al, 2003). In contrast, p53-deficient MEFs were able to form
immortalized colonies, although Trf1D/D K-Ras+/G12V p53/ MEFs
formed fewer and smaller colonies than Trf1+/+ K-Ras+/G12V p53/
MEFs. In summary, Trf1 deficiency limits both proliferation and
cellular immortalization of K-Ras-expressing cells in vitro even in
the absence of p53.
Trf1 deficiency impairs K-RasG12V-mediated lung cancer and
increases mouse survival even in the absence of p53
We next set out to determine the impact of Trf1 deficiency in vivo in
the K-Ras-induced lung carcinogenesis model. To this end, 8-week-
old Trf1lox/lox K-Ras+/G12V p53+/+ and Trf1lox/lox K-Ras+/G12V p53/
mice, as well as their respective Trf1 wild-type controls, were
infected by intratracheal instillation with replication-defective
adenoviruses encoding the Cre recombinase (adeno-Cre) (Materials
and Methods). This strategy allowed the expression of the resident
K-RasG12V oncoprotein simultaneously with the ablation of the
Trf1lox allele in the infected lung cells (Fig 1A). Nine weeks after
viral inoculation, tumor growth was measured by using computed
tomography (CT) every second week until 24th week post-infection
when the experiment was concluded. At 22 weeks post-infection,
positron emission tomography (PET) was performed to monitor
tumor malignancy (Fig 1B). At 24th week post-infection, the animals
were sacrificed to carry a full histopathological analysis of the lungs,
and to confirm K-RasG12V expression and Trf1 deletion in the
lesions (Fig 1B). Trf1 deletion was monitored in all tumors by
TRF1 immunofluorescence and by PCR (Fig 1C and D). K-RasG12V
expression in tumors was confirmed by detecting the expression of
its beta-galactosidase (b-geo) reporter (Fig 1E).
In vivo tumor follow-up by CT scan showed that in a p53-
proficient background, Trf1-deleted mice showed a delayed onset of
the first CT scan-detectable lesions from 9 weeks in Trf1 wild-type
lungs to 12 weeks in the Trf1-deleted ones (Fig 2A). However, after
this initial lag, both genotypes showed a similar growth of the
tumor lesions by CT scan (Fig 2A). Post-mortem lung analysis
revealed that the number of tumors per mouse was higher in Trf1
wild-type than in Trf1lox/lox mice although tumors were histologi-
cally identical (Fig 2B). Importantly, immunofluorescence analysis
of Trf1 expression showed that all tumors in Trf1-deleted lungs
were escapers and had normal Trf1 expression (Fig 2C). Thus, Trf1
is essential for K-RasG12V-induced lung tumor development in a p53-
proficient background as no tumors lacking Trf1 expression were
found (Fig 2C).
Next, we studied the impact of Trf1 deletion in K-RasG12V-
induced lung tumors in a p53-deficient background, a situation
that resembles many human lung tumors. CT analysis revealed
that Trf1D/D K-Ras+/G12V p53/ tumors grew markedly slower and
reached a smaller size at their end point than Trf1+/+ K-Ras+/G12V
p53/ tumors (Fig 2D and E). PET analysis at 22 weeks post-
infection revealed that Trf1D/D K-Ras+/G12V p53/ tumors showed
less metabolic activity than Trf1+/+ K-Ras+/G12V p53/ tumors
indicating a lower grade of malignancy (Fig 2F and G). Notably, in
agreement with the lower malignancy, Trf1lox/lox K-Ras+/G12V
p53/ mouse survival was significantly higher than that of Trf1+/+
K-Ras+/G12V p53/ mice (Fig 2H). Of note, in this setting only 5%
of the Trf1lox/lox p53/ tumors were found to be escapers
(Fig 2C).
By blind histopathological analysis of the lungs, we confirmed
that Trf1D/D K-Ras+/G12V p53/ lungs developed less carcinomas
than Trf1+/+ K-Ras+/G12V p53/ lungs (Supplementary Fig S2A–C).
In addition, the malignant lesions in Trf1D/D K-Ras+/G12V p53/
lungs were smaller compared to Trf1+/+ K-Ras+/G12V p53/ lungs
(Supplementary Fig. S2A–C). In summary, Trf1 deletion effectively
impairs progression to full-blown carcinomas even in the absence of
p53.
Trf1 abrogation induces telomeric DNA damage and apoptosis in
p53-deficient lung carcinomas
Previous reports have shown that abrogation of Trf1 in different cell
types causes a persistent DNA damage response at chromosome
ends, which leads to decreased cell viability (Martinez et al, 2009;
Sfeir et al, 2009; Beier et al, 2012; Schneider et al, 2013). To
address whether the decreased growth and lower malignancy of
Trf1-deficient lung tumors were associated with increased DNA
damage in the lesions, we quantified cH2AX DNA damage foci and
their colocalization to telomeres (the so-called telomere-induced foci
or TIFs) in lung carcinoma sections. The percentage of cH2AX-posi-
tive cells was significantly higher in Trf1D/D K-Ras+/G12V p53/
carcinomas compared to Trf1+/+ K-Ras+/G12V p53/ carcinomas
(Fig 3A). Furthermore, co-immunofluorescence staining of cH2AX
foci with RAP1, another shelterin component localized at telomeres,
showed increased number of DNA damage foci at telomeres in
Trf1D/D K-Ras+/G12V p53/ than in Trf1+/+ K-Ras+/G12V p53/
carcinomas (Fig 3B).
To address the cellular effects of increased telomere damage in
lung carcinomas, we first determined the percentage of apoptotic
cells in lung carcinoma lesions. The percentage of carcinoma cells
that were positive for the apoptotic marker active caspase-3 (AC3)
was higher in Trf1D/D K-Ras+/G12V p53/ carcinomas compared to
Trf1+/+ K-Ras+/G12V p53/ carcinomas (Fig 3C). Thus, Trf1 dele-
tion in lung carcinomas leads to increased telomeric damage and
subsequent induction of apoptosis.
Trf1 deficiency leads lower proliferation and increased G2 arrest
and mitotic defects in p53-deficient lung carcinomas
To determine whether Trf1 deletion in the context of K-RasG12V-
induced lung cancer also leads to proliferation defects, we
performed Ki67 immunohistochemistry directly on lung carcinoma
sections. We observed a lower proliferation index (Ki67-positive
cells) in Trf1D/D K-Ras+/G12V p53/ carcinomas compared to Trf1+/+
K-Ras+/G12V p53/ carcinomas (Fig 4A). To determine the cell
cycle phase where Trf1-deleted cells showed defects, we analyzed
the staining pattern of phospho-histone H3 (Ser10). A pH3 pan-
nuclear staining is a distinctive feature of mitotic cells, whereas pH3
foci are characteristic of G2 cells (Hendzel et al, 1991). We found
that the percentage of cells positive for G2-distinctive pH3 foci
pattern was significantly increased in Trf1D/D K-Ras+/G12V p53/
carcinoma lesions compared to Trf1+/+ K-Ras+/G12V p53/ lesions
(Fig 4B), suggestive of increased G2 arrest.
Persistent telomere damage can result in bypass of mitosis lead-
ing to endoreduplication and tetraploidy (Davoli et al, 2010). In line
with this, Trf1D/D K-Ras+/G12V p53/ carcinomas presented an
increased number of giant nuclei indicative of endoreduplication, as
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Figure 2. Trf1 deficiency impairs K-Ras-mediated lung cancer development.
A Tumor growth curve of Trf1+/+ K-Ras+/G12V p53+/+ and Trf1D/D K-Ras+/G12V p53+/+ measured by computed tomography (CT).
B Quantification of the number and size of Trf1+/+ K-Ras+/G12V p53+/+ and Trf1D/D K-Ras+/G12V p53+/+ carcinomas at death point.
C Percentage of tumors that have deleted Trf1 quantified by TRF1 immunofluorescence after mice had been sacrificed. Post-mortem analysis of Trf1 deletion in each
tumor revealed that none of the Trf1lox/lox K-Ras+/G12V p53+/+ ones had excised Trf1.
D Tumor growth curve and tumor growth slope of Trf1+/+ K-Ras+/G12V p53/ and Trf1D/D K-Ras+/G12V p53/ measured by CT.
E Tumor maximal section of Trf1+/+ K-Ras+/G12V p53/ and Trf1D/D K-Ras+/G12V p53/ lungs measured by histological analysis before death point by CT.
F Maximum 18F-FDG-glucose uptake by Trf1+/+ K-Ras+/G12V p53/ and Trf1D/D K-Ras+/G12V p53/ tumors 22 weeks after infection by positron emission tomography
(PET).
G Representative PET-CT image of Trf1+/+ K-Ras+/G12V p53/ and Trf1D/D K-Ras+/G12V p53/ lungs.
H Survival curve of Trf1+/+ K-Ras+/G12V p53/ and Trf1D/D K-Ras+/G12V p53/ mice.
Data information: Error bars represent standard error. t-test, chi-squared (B) test, or log-rank (Mantel–Cox; H) test was used to assess statistical significance. The number
of mice and the number of tumors are indicated in each case.
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Figure 3. Trf1-deficient carcinomas present high amount of telomeric DNA damage and apoptosis.
A Percentage of cells showing cH2AX foci in carcinomas of the indicated genotypes (left panel). Representative images of cH2AX immunohistochemistry (right panel).
B Percentage of cells showing 3 or more cH2AX and RAP1 colocalizing foci (TIFs) (left panel). Representative images of cH2AX and RAP1 double immunofluorescence
(right panel). Yellow arrowheads: colocalization of cH2AX and RAP1.
C Percentage of active caspase-3 (AC3)-positive cells (left panel). Representative images of AC3 immunohistochemistry (right panel).
Data information: Error bars represent standard error. The number of mice and carcinomas analyzed per genotype is indicated. t-test was used to assess statistical
significance.
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well as increased anaphase bridges, compared to Trf1+/+ K-Ras+/G12V
p53/ carcinomas (Fig 4C–E). Similarly, Trf1D/D K-Ras+/G12V
p53/ carcinomas presented cells showing bizarre multilobulated
nuclei and multipolar mitosis, which were not present in Trf1+/+
K-Ras+/G12V p53/ carcinomas (Fig 4E). This type of aberrant




Figure 4. Trf1 deficiency leads to G2 arrest and mitotic defects.
A Percentage of Ki67-positive cells in the carcinomas of the indicated genotypes (left panel). Representative images of Ki67 immunohistochemistry (right panel).
B Percentage of pH3-positive cells in the carcinomas of the indicated genotypes (left panel). Representative images of pH3 immunohistochemistry (right panel).
Red arrowheads: pH3-positive cells.
C Percentage of giant nuclei in the carcinomas of the indicated genotype.
D Percentage of anaphase bridges out of total anaphases in the carcinomas of the indicated genotypes.
E Representative images of giant nuclei, multilobulated nuclei, anaphase bridges, and multipolar mitoses. Red arrowheads indicate the corresponding mitotic
aberrations indicated in the image.
Data information: Error bars represent standard error. The number of mice and carcinomas analyzed per genotype is indicated. t-test was used to assess statistical
significance.
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(Vakifahmetoglu et al, 2008). These observations suggest that lung
carcinoma cells require TRF1 for proper completion of mitosis and
that Trf1 deletion leads to severe mitotic defects.
Trf1 downregulation in mouse cell lines derived from K-RasG12V
p53-deficient lung carcinomas as well as in human lung
cancer cell lines impairs cancer growth and metastasis in
xenograft models
To validate these results using an independent strategy to inhibit
TRF1, as well as to assess the effect of TRF1 abrogation in already
established K-Ras-induced lung tumors, we downregulated Trf1
expression by using shRNA technology in three K-RasD/G12Vgeo
p53/ mouse cancer cell lines derived from three independent
mouse lung carcinoma lesions and assessed the effects on tumor
growth using two independent allograft experiments. First, to
address the effect of TRF1 inhibition in tumor growth in vivo,
we subcutaneously injected 50,000 lung carcinoma cells into
immunodeficient mice and followed tumor onset and growth. Trf1
downregulation resulted in a marked delay in tumor onset as well
as in a significantly decreased tumor growth (Fig 5A–D).
Three weeks after injection, mice were sacrificed and the tumors
were histologically analyzed. We confirmed that Trf1 downregula-
tion was maintained during in vivo tumor development (Fig 5E).
Trf1-downregulated tumors showed decreased proliferation and
increased DNA damage as well as increased apoptosis compared to
controls (Fig 5F–H). Again, Trf1-downregulated tumors presented a
high proportion of aberrant nuclei and anaphase bridges (Fig 5I).
Next, to study the effect of TRF1 inhibition in the metastatic poten-
tial of established lung cancer cells induced by K-Ras expression,
we intravenously injected 150,000 K-RasD/LG12Vgeo p53/ lung cells
into immunodeficient mice. Tail vein injection of tumor cells
results in lung metastasis (Elkin & Vlodavsky, 2001). Three weeks
after injection, the mice were sacrificed and lungs were subjected
to full histopathology analysis. Again, we confirmed that Trf1
downregulation was maintained in the generated lung metastasis
(Fig 5J). Importantly, Trf1 downregulation resulted in smaller lung
metastasis (Fig 5K and I), coincidental with increased DNA
damage, decreased proliferation, and increased apoptosis compared
to the controls (Fig 5M–O). These results indicate that even a
partial decrease in TRF1 levels of approximately 50% in tumors
very significantly impairs lung tumor growth and lung metastasis,
arguing that putative small molecule inhibitors of TRF1 could be
effective.
Next, we tested whether TRF1 depletion had similar effects on
human lung cancer cell lines. To this end, we downregulated Trf1
levels by using shRNAs in a K-Ras-mutated human lung carcinoma
cell line, the A549 (ATCC n; CCL-185), a human lung cancer cell
line harboring wild-type p53 (Fig 5P). We then injected subcutane-
ously in immunodeficient mice 150,000 cells either infected with
sh-scrambled or Trf1-shRNA and followed tumor development.
TRF1 downregulation resulted in a markedly delayed tumor onset
and growth. Indeed, control cells started to develop tumors 11 days
after injection, while the latency of TRF1-depleted cells was of
17 days. Moreover, after 24 days of follow-up, only two out of eight
injections with TRF1-downregulated cells were able to generate
tumors whose growth were significantly impaired as compared to
control cells (Fig 5Q and Supplementary Fig S3). Thus, TRF1
downregulation blocks the growth of cell lines derived from already
formed lung mouse tumors and has proven efficacy in one human
cancer cell line.
Trf1 deficiency impairs lung carcinomas independently of
telomere length
To demonstrate that the increased apoptosis and proliferation
defects observed in Trf1-deleted lung carcinomas were not due
to shorter telomeres compared to the TRF1-proficient tumors, we
determined telomere length by telomere quantitative FISH
directly on lung carcinoma sections. Indeed, telomeres were
longer in the Trf1D/D K-Ras+/G12V p53/ carcinomas compared
to Trf1+/+ K-Ras+/G12V p53/ carcinomas (Supplementary Fig
S4A–C). As telomere length reflects the proliferative history of a
given tissue, the observation that Trf1+/+ K-Ras+/G12V p53/
carcinomas present shorter telomeres than TRF1-deficient ones is
likely to reflect the lower proliferation rate of TRF1-deficient
tumors.
Whole-body Trf1 depletion allows normal mouse survival and
normal tissue function
A prerequisite that must be fulfilled by any potential anti-cancer
target is that its systemic inhibition in healthy tissues does not
compromise organism viability. It has been shown that Trf1 deletion
is deleterious at early points of development (Karlseder et al, 2003;
Martinez et al, 2009). In addition, acute TRF1 removal from bone
marrow in 8-week-old mice leads to bone marrow failure (Beier
et al, 2012). To validate TRF1 as a therapeutic drug target in lung
cancer treatment, we set out to analyze the effects of whole-body
TRF1 depletion in the context of adult mice and its impact on long-
term mouse viability. To this end, we first generated a new mouse
model, Trf1lox/lox hUBC-CreERT2 mice, in which the expression of
CreERT2 is transcriptionally controlled by the ubiquitously and
constitutively regulated ubiquitin promoter (Ruzankina et al, 2007;
Martinez et al, 2009) (Fig 6A). Then, twelve-week-old Trf1+/+ hUBC-
CreERT2 and Trf1lox/lox hUBC-CreERT2 mice were subjected to a
tamoxifen-containing diet for 7 weeks in order to induce Trf1 dele-
tion. After this period of time, a total of eight mice of each genotype
were sacrificed to analyze the extent of Trf1 deletion in a panel of
different tissues as well as to perform full histopathological analysis.
qPCR analysis showed that Trf1 had been successfully deleted from
heart, intestine, lung, skin, blood, liver, kidney, bone marrow, brain,
and stomach (Fig 6B). TRF1 immunofluorescence in skin and small
intestine sections confirmed partial depletion of TRF1 protein in
these tissues (Fig 6C). Despite successful TRF1 depletion after
7 weeks in a tamoxifen-containing diet, neither Trf1+/+ nor Trf1D/D
showed signs of viability loss or decreased survival (Fig 6D). Histo-
pathological analysis of the tissues revealed that the Trf1D/D hUBC-
CreERT2 mice showed alterations in rapidly proliferating tissues
consistent with the stem cell compartment being affected (Fig 6E).
TRF1-depleted basal skin, intestinal crypts, and bone marrow
progenitors presented anisocytosis (Supplementary Figs S5 and S6).
Trf1-deficient basal skin displayed areas with low cellularity and
follicular cysts (Fig 6E and Supplementary Fig S5A). Trf1D/D intesti-
nal crypts showed an increased number of mitosis, but the microvilli
length was normal (Fig 6E and Supplementary Fig S5B). Trf1D/D
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bone marrow presented megakaryocytes with reduced cytoplasm
(Fig 6E and Supplementary Fig S6A). Blood counts showed a small
decrease in the number of platelets and lymphocytes (Fig 6F). Of
note, only one Trf1D/D hUBC-CreERT2 mouse showed a moderate
bone marrow aplasia (Fig 6E and Supplementary Fig S6A). Of note,
6 months on tamoxifen diet did not further decrease Trf1 expression
as compared to the levels observed after 7 weeks and did not aggra-
vate neither pathologies nor mouse viability (Fig 6G and data not
shown). Importantly, tamoxifen retrieval from the diet resulted in a
rescue of pathologies as well as in a recovery of Trf1 expression
levels (Fig 6E–G). Indeed, after 3 weeks, placing the mice on stan-
dard diet Trf1 levels in blood, intestine, skin, and bone marrow
increased 20-, 10-, 30- and 200-fold, respectively, compared to the
levels observed in mice on tamoxifen diet. However, recovery of
Trf1 expression did not reach wild-type levels (Fig 6G). After
3 weeks and 4 months on standard diet, platelet blood counts were
also recovered to wild-type levels (Fig 6F). Thus, a partial ubiquitous
TRF1 downregulation, although resulting in decreased cellularity in
some highly proliferative compartments, such as the bone marrow
and the blood, is compatible with mouse viability.
Identification of chemical compounds that disrupt TRF1 binding
to telomeres
We next set out to identify chemicals that disrupt TRF1 binding to
telomeres. To do so, we designed a cell-based system for high-
throughput screening. Induced pluripotent stem (iPS) cells derived
from eGFP-TRF1 knock-in (KI) mouse embryo fibroblasts (MEFs)
were used (Schneider et al, 2013). The eGFP-TRF1 protein forms
fluorescence foci localizing at the telomere that strongly decrease in
intensity in control cells expressing a sh-Trf1 or in cells heterozy-
gous for eGFP-TRF1 expression (eGFP-Trf1+/KI) showing that this
cellular system is an excellent tool to track TRF1 and telomeres
in vivo (Supplementary Fig S7A). Homozygous version (eGFP-
Trf1KI/KI)—with strong foci intensity—, heterozygous version
(eGFP-Trf1+/KI) and knockdown for TRF1 (sh-Trf1)—with low foci
intensity—were used to validate this system (Supplementary Fig
S7B). The Z’-factor coefficient, a statistical parameter that in addi-
tion to considering the window in the assay also considers the vari-
ance around both the high and low signals in the assay, is
commonly used to assess the robustness of high-throughput
screening (HTS) assays. The Z’-factor was calculated as follows:
Z’-factor = 1  3 × (sp + sn)/|mp  mn|, where m: mean fluores-
cence intensity and s: standard deviation; n: negative control
(sh-Trf1 or eGFP-Trf1+/KI heterozygous, minimum signal) and p:
positive control (homozygous eGFP-Trf1KI/KI, maximum signal). A
Z’-factor value of 0.75, when comparing homozygous (homo) vs.
heterozygous (het) or 0.86 comparing homo vs. sh-Trf1, confirmed
the feasibility of this screening system (Supplementary Fig 7C). We
carried out a screening campaign using a small collection of 640
compounds selected as representative of the ETP-CNIO library
(Materials and Methods). Screening was performed at 8 h and at
12.5 lM final concentration on eGFP-Trf1KI/KI cells. Foci distribution
of the homozygous eGFP-Trf1KI/KI (control) or sh-Trf1, were taken
as internal controls. Compounds decreasing percentage of high-
intensity foci above 25% of the control were selected as “hit” candi-
dates, for further validations. In addition, the number of nuclei was
counted. Compounds significantly affecting cell viability were not
considered as positive “hits”.
The screening retrieved a number of positive hits belonging to
different chemical classes. The identified hits were newly resyn-
thesized and tested confirming the observed activity. The search
for analogues within the ETP-CNIO library and their screening
identified additional active compounds. Among the different hits,
two of them were selected for further biological investigation
attending to their primary activity as “TRF1 inhibitors” and addi-
tionally to their potential to be used as tool compounds for
in vivo validation experiments. The selected hits ETP-47228 and
ETP-47037 are included as examples in CNIO international patent
applications WO2010119264 and WO2011089400, respectively.
The general structures of both compounds are depicted in
Supplementary Fig S8A.
We next validated our hits by measuring eGFP-TRF1 fluorescence
intensity in e-GFP-Trf1KI/KI iPS cells after treatment with DMSO, ETP-
47228, or ETP-47037 for 8 h at 10 lM. iPS cells transduced with a
sh-Trf1 were used as a positive control. Both ETP-47228 and
ETP-47037 induced a decrease of 31.33 and 27.32%, respectively, of
e-GFP-TRF1 levels, as compared to a 57% decrease observed in cells
treated with sh-Trf1 (Supplementary Fig S7D).
To address whether these compounds also decrease endogenous
TRF1 levels, we treated wild-type iPS cells (eGFP-Trf1KI/KI)
with 10 lM ETP-47228 for 8 h and quantified TRF1 levels by
Figure 5. Trf1 downregulation in K-RasG12V-transformed lung cells leads to a decreased tumor growth and decreased metastatic potential in allograft and
xenograft models.
A–C The latency (A), volume (B), and weight (C) of subcutaneous tumors generated by control and Trf1-downregulated K-RasG12V-transformed lung cells in athymic
mice.
D Representative images of the subcutaneous tumors.
E Trf1 expression levels measured by qPCR in the injected cell line and in the generated subcutaneous tumors.
F–H Number of Ki67-positive (F), number of cH2AX-positive (G), and number of active caspase-3-positive (H) cells per field in the subcutaneous tumors.
I Representative images of aberrant giant nuclei and anaphase bridges in the Trf1-downregulated subcutaneous tumors compared to the normal nuclei of control
tumors.
J TRF1 immunofluorescence shows the downregulation of Trf1 in lung tumors of the mice intravenously injected with control and Trf1-downregulated cells.
K Tumor area measured in the lungs of the mice intravenously injected with control and Trf1-downregulated cells.
L Representative images of the lungs colonized by control and Trf1-downregulated cells, respectively.
M–O Number of Ki67-positive (M), number of cH2AX-positive (N), and number of active caspase-3-positive (O) cells per field in the lung tumors.
P Trf1 expression levels measured by qPCR in the A549 cell line infected either with sh-scrambled or sh-Trf1.
Q Growth of A549-derived tumors.
Data information: Error bars represent standard error. The number of mice and tumors analyzed per condition is indicated. t-test was used to assess statistical
significance.
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immunofluorescence. Cells treated with ETP-47228 contained 25%
lower levels of TRF1 signal as compared to control cells treated with
DMSO (Supplementary Fig S9A). Interestingly, neither the Trf1
transcriptional levels nor the total TRF1 protein levels were affected
by ETP-47228 or ETP-47037 (Supplementary Fig S9B). In analogy to
Trf1 genetic ablation, chemical inhibition of TRF1 foci intensity was
accompanied by increased cH2AX DNA damage foci and increased
telomeric DNA damage foci (TIFs), together with impairment of
cellular proliferation with increasing ETP-47228 concentrations
(Supplementary Fig S9C–E).
Effective chemical Trf1 inhibition in lung adenocarcinoma-
derived cells
Next, we treated lung mouse adenocarcinoma cell lines with 10 lM
of both ETP-47228 and ETP-47037 for 24 and 48 h and quantified
TRF1 levels compared to DMSO-treated cells. Again, treatment of
lung cancer cells with both ETP-47228 and ETP-47037 resulted in
decreased TRF1 foci levels, increased cH2AX foci, as well as induc-
tion of TIFs (Fig 7A–C). Similarly, both compounds affected prolifer-
ation from concentrations of approximately 5 lM (Fig 7D).
Next, we generated allograft mouse models with lung cancer
cells pretreated with either DMSO, ETP-47228, or ETP-47037 and
followed tumor onset and growth during 12 days. Treatment with
both compounds significantly impaired initial tumor development in
allograft models (Fig 7E).
In vivo treatment with ETP-47037 disrupts TRF1 and effectively
impairs lung carcinoma progression
Next, we addressed whether TRF1 chemical inhibitors administered
in vivo could inhibit the growth of already established K-RasG12V
lung carcinomas lacking p53. To this end, we selected compound
ETP-47037 owing to its in vivo pharmacokinetic properties. ETP-
47037 pharmacokinetic properties were determined after IV and PO
(per os) administration in BALB/c mice at doses of 3.0 and 9 mg/kg
of body weight, respectively (Supplementary Fig S8). In particular,
ETP-47037 is an orally bioavailable compound with an absorbed
fraction F = 29.5%. The half-life after IV administration is 0.5 h,
and the same parameter in the oral arm extends up to 5.2 h. ETP-
47037 is highly stable in vivo with a total clearance of 0.65 l/h/kg,
which means 12% of the hepatic blood flow for mice. The
compound is distributed in tissues, as inferred by a volume of distri-
bution of 0.6 l/kg similar to the total body water content (Supple-
mentary Materials and Methods).
Mice with already developed p53-null lung carcinomas were
treated by oral gavage during 10 days (8 days in total with a 2-day
gap) with 75 mg/kg body weight of ETP-47037. Control mice were
similarly treated with vehicle. Previously to the start and at the
end of the treatment, mice were subjected to computerized tomogra-
phy (CT) for quantification of tumor growth area. Strikingly,
10 days of treatment with this compound effectively impaired the
progression of already formed lung carcinomas compared to
the group treated with vehicle (Fig 8A and B). Of note, one of the
tumors detected before the treatment was located in a highly inflam-
matory region, and for this reason, we could not accurately deter-
mine its size before the treatment (white arrowhead in Fig 8B).
TRF1 foci levels were significantly decreased in tumor samples as
well as in intestines of mice treated with ETP-47037 compared to
the vehicle (Fig 8C). Decrease in TRF1 foci signal was accompanied
with a significant increase in cH2AX-positive cells in both intestines
and lung tumors (Fig 8D). In addition, ET-47037-treated tumors
showed a significant decrease in proliferating and mitotic cells and
increase in the number of G2-arrested cells (Fig 9A–D). Importantly,
Figure 6. Systemic Trf1 depletion in healthy tissues does not compromise tissue function nor organism viability.
A Trf1lox/lox hUBC-CreERT2 genetic mouse model.
B Trf1 expression levels in the indicated tissues of wild-type and Trf1lox/lox hUBC-CreERT2 mice subjected to a tamoxifen-containing diet for 7 weeks.
C Representative images of TRF1 immunofluorescence and quantification of the percentage of TRF1-positive cells in skin and intestine sections of wild-type and
Trf1lox/lox hUBC-CreERT2 mice subjected to a tamoxifen-containing diet for 7 weeks.
D Survival curve of wild-type and Trf1lox/lox hUBC-CreERT2 mice subjected to a tamoxifen-containing diet for 7 weeks.
E Quantification of the histological alterations observed in tamoxifen-treated Trf1lox/lox hUBC-CreERT2 mice and 4 months after tamoxifen retrieval compared to their
wild-type counterparts.
F Quantification of blood cell populations in wild-type and Trf1lox/lox hUBC-CreERT2 mice subjected to a tamoxifen-containing diet for 7 weeks and after 3 weeks and
4 months of tamoxifen retrieval.
G Trf1 expression levels in blood, intestine, skin, and bone marrow of Trf1lox/lox hUBC-CreERT2 mice subjected to a tamoxifen-containing diet either for 7 weeks or for
6 months and after 3 weeks tamoxifen retrieval compared to wild-type mice.
Data information: Error bars represent standard error. The number of mice analyzed per genotype is indicated in each case. t-test was used to assess statistical
significance. TMX, tamoxifen.
Figure 7. Efficient chemical inhibition of TRF1 telomere binding by compounds ETP-47228 and ETP-47037 in mouse lung adenocarcinoma-derived cells.
A Quantification of TRF1 levels by immunofluorescence in lung tumor-derived cell line treated with DMSO, with 10 lM ETP-47228 (24 h), and with 10 lM ETP-47037
(48 h). Representative images are shown to the right.
B Quantification of cH2AX levels by immunofluorescence in lung tumor-derived cell line treated with DMSO, with ETP-47228 (24 h), and with ETP-47037 (48 h).
Representative images are shown to the right.
C Quantification of telomere-induced foci (TIFs) by double immunofluorescence with anti-RAP1 and anti-cH2AX antibodies. Representative images are shown to the
right. White arrowheads: colocalization of cH2AX and RAP1.
D Effect of different ETP-47228 and ETP-47037 concentrations during 24 h on proliferation in lung tumor-derived cell line relative to the growth of DMSO-treated cells.
E Tumor growth quantification in allograft model ETP-47037 or with ETP-47228.
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during the treatment, the mice showed a normal viability and did
not show any signs of sickness. Histopathological analysis of the
intestine did not reveal any apparent lesion although we saw
increased aberrant mitotic figures and nuclei characteristic of TRF1
inhibition (Fig 9E). In bone marrow, moderate aplasia, necrotic
cells, and hemosiderosis were observed. In the skin, multinucleated
cells and giant nuclei were detected (Fig 9F), a hallmark of TRF1
targeting. Of note, ETP-47037 did not induce changes in telomere
length in treated tumors as compared to untreated ones (Fig 9G).
These findings indicate that TRF1 inhibition can be achieved in vivo
using chemical compounds and that there is a therapeutic window




Figure 8. “In vivo” treatment with ETP-47037 compound blocks the progression of lung carcinoma.
A Schematic representation of the ETP-47037 treatment protocol. Mice with already developed lung carcinomas were subjected to computerized tomography (CT)
measurements before the start of the treatment. ETP-47037 was given at a dose of 75 mg/kg body weight by oral gavage 8 days out of the ten that the experiment
lasted as indicated. At the end of the treatment, a CT was performed for quantification of tumor area and mice were sacrificed for further histological and molecular
analysis. Control mice were similarly treated with vehicle.
B Quantification of tumor growth relative to initial tumor size. Representative CT images are shown to the right. The white arrowhead indicates a tumor within a
highly inflammatory region.
C Quantification of TRF1 levels by immunofluorescence in intestine and lung tumors samples of mice treated with vehicle or with ETP-47037 for 10 days.
Representative images are shown to the right (n = 4).
D Number of cells showing cH2AX foci in intestine and lung tumors samples of mice treated with vehicle or with ETP-47037 for 10 days. Representative images are
shown to the right (n = 4).
Data information: The data represent the mean values obtained from three mice in each group. Error bars represent standard errors. t-test was used to assess statistical
significance.
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Figure 9. “In vivo” treatment with ETP-47037 compound does not compromise tissue viability.
A–C Quantification of the number of (A) Ki67-, (B) pan-nuclear p-H3 pattern-, and (C) foci p-H3 pattern-positive cells in untreated and ETP-470037-treated lung
carcinomas. The data represent the mean values obtained for three mice in each group. Error bars represent standard errors.
D Representative Ki67 and p-H3 images.
E Representative H&E images of intestine samples corresponding to untreated and ETP-47037-treated animals. High-magnification images are shown to the right
indicating the presence of normal mitosis, giant multinucleated and aberrant mitotic figures.
F Representative H&E images of bone marrow and skin samples corresponding to untreated and ETP-47037-treated animals. High-magnification images are shown
indicating the presence of necrosis, hemosiderosis, multinucleated cells, and giant nuclei. Bone marrow showed moderated aplasia.
G Telomere length in untreated and ETP-47037-treated lung tumor samples. Representative images are shown to the right.
Data information: t-test was used to assess statistical significance.
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Discussion
Aberrant telomerase activation is a common feature of human
cancers, where it allows the growth of malignant cells by ensuring
maintenance of a minimal functional telomere length that permits
cell division (Kim et al, 1994; Hahn et al, 1999; Gonzalez-Suarez
et al, 2000). Indeed, mutations in the telomerase gene or its
regulatory regions have been found associated with many different
types of cancer (McKay et al, 2008; Wang et al, 2008; Rafnar et al,
2009; Shete et al, 2009; Petersen et al, 2010; Melin et al, 2012;
Bojesen et al, 2013; Garcia-Closas et al, 2013; Horn et al, 2013;
Huang et al, 2013). To date, targeting of telomeres in human
cancer has been mainly via targeting telomerase activity, typically
through direct small molecule inhibitors of the enzyme activity
(Brennan et al, 2010; Joseph et al, 2010), or through immunother-
apy-based approaches (Brunsvig et al, 2006; Suso et al, 2011).
Telomeric repeats can also form DNA higher order structures
known as G-quartets, and molecules that stabilize G-quartets have
also been proposed to inhibit telomerase-mediated telomere elonga-
tion in cancer (Sun et al, 1997; Shin-ya et al, 2001; Huang et al,
2008). A predicted shortcoming of therapeutic strategies based on
telomerase inhibition to treat cancer is that they will be effective only
when telomeres shorten below a minimum length. Indeed, telomer-
ase activity is dispensable for transformation of cells with long telo-
meres (Seger et al, 2002), and studies with telomerase inhibitors
indicate that they are effective preferentially in cells with short telo-
meres (Hahn et al, 1999; Herbert et al, 1999; Wang et al, 2004; Bren-
nan et al, 2010; Wu et al, 2012; reviewed in Buseman et al, 2012).
In line with this, telomerase abrogation in the context of cancer-
prone mouse models, including the K-Ras+/G12D lung tumorigenesis
mouse model, only showed anti-tumorigenic activity after several
mouse generations in the absence of telomerase when telomeres
reached a critically short length (Chin et al, 1999; Greenberg et al,
1999; Gonzalez-Suarez et al, 2000; Perera et al, 2008). Moreover,
these anti-tumorigenic effects of short telomeres owing to telomerase
deficiency are abrogated in the absence of p53 (Chin et al, 1999;
Greenberg et al, 1999).
In contrast to telomerase inhibition, telomere uncapping has
been shown to cause rapid induction of cell death and/or senes-
cence in a manner that is independent of telomerase activity and
telomere length (Karlseder et al, 1999; Smogorzewska & de Lange,
2002; Martinez et al, 2009). Owing to the fact that telomere uncap-
ping can be achieved independently of telomere length, it emerges
as a more universal way to rapidly impair the growth of dividing
cells. Indeed, in our experimental system, Trf1 abrogation results in
a dramatic reduction in the number and the size of malignant lung
carcinoma lesions, even in the absence of p53, already in the first
mouse generation and in the absence of telomere shortening, indi-
cating that Trf1 deficiency severely impairs cancer progression in
the context of oncogenic K-Ras. As a consequence of this, all the
Trf1D/D K-Ras+/G12V p53/ mice survived until the end point of the
experiment (24 weeks post-infection), while only 50% of the Trf1+/+
K-Ras+/G12V p53/ mice survived the same period. These findings
indicate that Trf1 deficiency impairs the development of K-Ras-
induced lung carcinomas. Of note, this represents the first time
that effective impairment of K-Ras+/G12V p53/ carcinomas is
achieved, as genetic abrogation of other therapeutic pathways did
not impair tumor growth in the absence of p53 (Navas et al,
2012). Furthermore, here we show that downregulation of Trf1 can
also block the growth and metastatic potential of both mouse and
human lung cancer cell lines derived from already established
K-Ras-induced lung carcinomas by using xenograft models.
We find that the mechanisms through which Trf1 deletion
impairs cancer progression are related to its previously described
roles in telomere capping, telomere replication, and mitosis (Marti-
nez et al, 2009; Sfeir et al, 2009). In this regard, we show that Trf1
deficiency results in a high burden of telomeric DNA damage, genetic
instability, proliferation defects, apoptosis, and mitotic catastrophe.
Importantly, we demonstrate here that a long-term systemic
depletion of TRF1 in healthy adult tissues does not compromise
organism viability, although we observed decreased cellularity in
some highly proliferative compartments, such as the hematopoietic
compartment and blood, which were recovered upon tamoxifen
removal. Together, these findings suggest a therapeutic window for
TRF1 inhibition in cancer.
Inspired by the above notion, we have identified compounds
that disrupt TRF1 binding to telomeres illustrating the feasibility of
chemically targeting shelterin proteins. Furthermore, we have
shown that “in vivo” treatment of already established lung
adenocarcinomas with one of the identified compounds,
ETP-47037, results in decreased TRF1 signal in vivo and the
impairment of tumor progression in the absence of decreased
mouse viability.
In summary, the results described here are proof of concept that
TRF1 abrogation is an effective therapeutic strategy to block the
growth of aggressive lung carcinomas independently of telomere
length and p53 status and that it is possible to achieve this by small
molecules that are able to target TRF1 in vivo. Finally, as this strat-
egy relies on a universal mechanism, namely induction of telomere




K-Ras+/LSLG12Vgeo (Guerra et al, 2003), and Trf1lox/lox (Martinez et al,
2009), p53/ (Jackson Labs, http://jaxmice.jax.org/strain/
002101.html) strains were crossed to obtain K-Ras+/LSLG12Vgeo
Trf1lox/lox p53/ mice. To generate Trf1lox/lox hUBC-CreERT2 mice,
we crossed our Trf1lox/lox (Martinez et al, 2009) with a mouse
strain that carries a ubiquitously expressed, tamoxifen-activated
recombinase, hUBC-CreERT2mice (Ruzankina et al, 2007). Trf1lox/lox
hUBC-CreERT2 mice were fed ad libitum for 7 weeks with tamoxi-
fen-containing diet (Tekland CRD Tam400/CreER). For allograft
experiments, 7-week-old athymic nude females were obtained from
Harlan. All mice were maintained at the Spanish National Cancer
Center under specific pathogen-free conditions in accordance with
the recommendations of the Federation of European Laboratory
Animal Science Associations (FELASA). All animal experiments
were approved by the Ethical Committee and performed in accor-
dance with the guidelines stated in the International Guiding Prin-
ciples for Biomedical Research Involving Animals, developed by
the Council for International Organizations of Medical Sciences
(CIOMS).
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Adenovirus intratracheal infection
Eight- to ten-week-old mice were treated once with intratracheal
adeno-Cre (Gene Vector Core, University of Iowa, 1 × 1010 pfu/ml)
instillation with 1 × 108 PFU/mouse of virus after anesthesia by
intraperitoneal injection of ketamine–medetomidine (Domitor,
1 mg/ml; Orion Corporation). To wake up the mice after the instilla-
tion, they were injected with 0.05 mg of atipamezole (Antisedan,
5 mg/ml; Orion Corporation).
In vivo imaging by computed tomography (CT) and positron
emission tomography (PET)
Nine weeks after inoculation, an in vivo follow-up of tumor growth
was achieved by six computed tomographies (CT) every 15 days.
PET was performed 22nd week post-inoculation, and the mice were
sacrificed (24th week post-inoculation). CT and PET analyses were
performed as previously described (Ambrogio et al, 2014). For PET
quantification, tumor regions of interest (ROIs) were selected in
the PET-CT overlapped image. In these ROIs, the standardized
18FDG-glucose uptake value (SUV) was calculated using the follow-
ing formula: SUV = tumor FDG concentration (MBq)/(injected
dose/body weight).
Telomere length analyses on tissue sections
Quantitative telomere fluorescence in situ hybridization (Q-FISH)
directly on tumor sections was performed as previously described
(Flores et al, 2008) and analyzed by Definiens software.
Chemical library
The Experimental Therapeutics Program at CNIO, ETP-CNIO,
owns a chemical library of about 50,000 single compounds built
as a result of the consolidation of several sub-libraries selected
attending to different criteria such as chemical diversity, kinase-
targeted focus, potential to disrupt protein–protein interactions,
and the presence of low molecular weight compounds to facili-
tate fragment-based drug discovery. The drug-likeness of the
whole library was also ensured by the application of filters such
as “rule of five” (Lipinski, 2004). The compounds were selected
from commercial origin as well as from internally newly
designed and synthesized chemical matter. Representative
libraries of the whole 50K library with smaller sizes were defined
after clustering, based on similarity analysis, and selection of
representative compounds from each cluster. A 640-compound
library, subject of the currently reported screening campaign, is
the minimum size set of compounds representing the chemical
ETP-CNIO collection.
Screening for identification of TRF1 inhibitors
We tested the CNIO-640 library previously described. iPS cells
expressing eGFP-TRF1 were seeded in 0.1% gelatin-pretreated cell-
carrier black 384-well microplates (Perkin Elmer) at a density of
1.25 × 104 cells per well 24 h before adding the compounds.
Compounds were weighed out and diluted in dimethyl sulfoxide
(DMSO) to a final concentration of 10 mM (mother plate). From
here, an intermediate dilution plate was prepared. The appropriate
volume (ll) of each compound solution was added automatically
(Beckman FX 96 tip) from the intermediated plate to the media of
plated cells to get a 12.5-lM final concentration for each compound
assayed in duplicate. Cell viability was previously tested in a dose
curve with increasing concentrations of DMSO. After 8-h incubation,
cells were fixed in 4% paraformaldehyde in phosphate-buffered
saline (PBS) for 15 min at room temperature and washed three
times with PBS. Those compounds that killed cells at 12.5 lM at 8 h
were not considered as positive hits.
For quantitative measurement of eGFP-TRF1 foci levels,
pictures of fixed cells were automatically acquired from each well
by the Opera High Content Screening (HCS) system (Perkin
Elmer). Sixty images of random fields per well, with a
40× magnification lens, were taken under non-saturating condi-
tions. At least 1 × 103 cells were analyzed for each well. Briefly,
images were segmented using the DAPI staining to generate
masks matching cell nuclei from which eGFP-TRF1 foci were
analyzed. SPSS software was used for statistical analysis as
follows: Within each plate, the eGFP-TRF1 intensities of control
eGFP-Trf1KI/KI cells were distributed by quartiles (Q). First-quartile
distribution (Q1) was taken as threshold to distinguish low- or
high-intensity eGFP-TRF1 foci. Percentage of low vs. high GFP-
TRF1 levels was normalized using the average of negative and
positive controls as minimum and maximum reference levels. The




Unlimited cell division in cancer requires activation of mechanisms
that ensure maintenance of telomere length. Targeting of telomeres
in human cancer has been approached via targeting telomerase
activity. A caveat of therapeutic strategies based on telomerase
inhibition to treat cancer is that they will be effective only when
telomeres shorten below a minimum length. We have addressed
whether induction of telomere dysfunction independently of telo-
mere length by targeting a shelterin component could be applied
as a more universal way to rapidly impair the growth of dividing
cells.
Results
We demonstrate that acute telomere uncapping owing to inhibition
of the TRF1 shelterin component has therapeutic activity in blocking
the growth of p53-deficient K-Ras-induced lung tumors by inducing
DNA damage at telomeres. This anti-tumorigenic activity of TRF1 inhi-
bition is independent of telomere length. In parallel, we show that
whole-body partial TRF1 depletion, although resulting in moderate
loss of cellularity in the bone marrow in few Trf1-deleted mice, did
not impair organismal viability and survival. Importantly, we identify
small molecules that disrupt TRF1 binding in vivo, and that effectively
block the growth of already established p53-deficient K-Ras-induced
lung carcinomas through induction of DNA damage and cell arrest,
again in the absence of deleterious effects in mouse survival or
viability.
Impact
This represents the first demonstration that targeting the TRF1 shel-
terin component may represent a novel therapeutic approach for
cancer treatment.
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In vivo treatment with compound ETP-47037
K-Ras+/LSLG12Vgeo Trf1lox/lox p53/ tumors were induced by intra-
tracheal adeno-Cre instillation as described above. Once the lung
tumors developed, mice were daily dosed orally with 75 mg/kg of
ETP-47037 formulated in 10% N-methyl-pyrrolidone and 90% poly-
ethylene-glycol 300 for 10 days and 2 days of resting. The reduction
in number and size of the tumors was analyzed by computed
tomography (CT).
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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